Dynavax Technologies (NASDAQ:DVAX) and the Coalition for Epidemic Preparedness Innovations (CEPI) have collaborated to develop a vaccine to prevent COVID-19.
Dynavax will make the toll-like receptor 9 (TLR9)
agonist adjuvant, CpG 1018, available for the development of effective
vaccines against COVID-19.
CpG 1018 is the adjuvant used in
HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]. It provides a
well‑developed technology and a safety database, accelerating the
development and large-scale manufacturing of a COVID-19 vaccine.
https://seekingalpha.com/news/3555404-dynavaxplus-19-premarket-on-coronavirus-vaccine-deal-cepi
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.